Skip to main content
OpenTrials
Completed

NCT Number: NCT06579885

Ocular Complications of Mpox in the Democratic Republic Congo

This is an observational study in which patients diagnosed with mpox will be enrolled, will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox. The study will primarily assess the presence of ophthalmological signs and symptoms at enrollment.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Kamituga General Hospital

Kamituga, South Kivu, Democratic Republic of the Congo

About this study

This is an observational study in which patients diagnosed with mpox will be enrolled in two clinics in remote settings in the DR Congo (Tunda and Kole general hospital) where mpox outbreaks are ongoing. After providing informed consent, participants will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox. This includes history taking, clinical examination, technical examinations such as a dilated fundoscopic exam, a fluorescein test and a Schirmer test, and a conjunctival swab for tear collection for monkeypox virus (MPXV) detection. Pictures of the anterior and posterior segment will also be taken to aid later verification and interpretation of the study findings. If they are hospitalised for mpox (for clinical reasons or as part of their participation in another ongoing clinical trial at the study sites), they will be followed up for 14 days and examined during an unscheduled visit in the case of new or worsening severe issues. Otherwise, patients are followed up at day 14 (for those hospitalised), day 28 and day 59. Study participants will receive the same supportive eye care as non-study participants. Study participants will be compensated for their time lost and for transportation to the clinic.

The study will primarily assess the presence of ophthalmological signs and symptoms at enrollment, but also aims to describe the complications of mpox that may arise after that point in time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient of any age or gender with laboratory-confirmed infection with MPXV
  • Laboratory confirmation of MPXV infection less than 48 hours before inclusion
  • Patient or culturally acceptable representative is willing and able to give informed consent or assent for participation in the study

Exclusion criteria

  • Patients for whom, in the judgment of the recruiting physician, participation in the study would interfere with routine optimal clinical care.

Treatment and study plan

Primary outcomes

  1. Composite presence or absence of eye disease and visual deficiencies at presentation

    Time frame: At enrollment

    Composite presence of

    • orbital lesions (exophthalmos, enophthalmos, oculomotor paralysis...)
    • affection of the adnexa
    • affection of the anterior segment
    • affection of the posterior segment
    • affection of the optic nerve

Secondary outcomes

  1. Ocular signs & symptoms at presentation and during follow-up

    Time frame: From enrollment until last follow-up

    Presence or absence of individual symptoms and signs over time

  2. Visual acuity at presentation and during follow-up

    Time frame: From enrollment until last follow-up

    Result of Optotype letters/numbers and/or E test over time

  3. presence of MPXV in tear fluid at presentation and during follow-up

    Time frame: From enrollment until last follow-up

    Result of MPXV-Polymerase Chain Reaction (PCR) on conjunctival swabs over time

Sponsors and collaborators

Lead sponsor

Institute of Tropical Medicine, Belgium

Other

Collaborators

  • Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

Mapping the Burden of Ocular Complications of Mpox in the Democratic Republic Congo (DRC)

Acronym: MPOX-EYE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 30, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.